DIP2C and colorectal cancer: We then targeted the human colorectal cancer cell line RKO, also well known to function with rAAV technology, and obtained three heterozygous knock-out clones (DIP2C+/− #1-3) following screening of 605 Geneticin-resistant clones, indicating <1% targeting efficiency.